Optimi Health Corp. (OPTHF) — Optimi Health said it is extending its Health Canada-licensed GMP manufacturing platform to include ibogaine, having secured naturally derived supply from two sources in both hydrochloride and freebase form.
The company plans 50 mg and 100 mg encapsulated dosage formats, positioning itself to support research after the executive order named ibogaine among prioritized compounds. The initiative broadens Optimi's psychedelic manufacturing beyond psilocybin and MDMA.
Source: stocktitan.net
For the rest of that week's sector news, read our week in review.